公費疫苗 COVID-19 Prevention in persons >18 years of age(仿單連結)

Vaccine, Subunit

Hypersensitivity to COVID-19 vaccine (subunit) or any component of the formulation.

Pregnant patients were excluded in initial phase 3 studies. Outcome data following inadvertent exposure during pregnancy are limited.

It is not known if components of this vaccine are present in breast milk.

>10%:
Nausea, vomiting, pain at injection site, tenderness at injection site, fatigue, headache, malaise, arthralgia, myalgia
1%-10%:
Erythema / swelling at injection site, limb pain, fever
<1%:
Myocarditis (18 to 19 years of age)

IM 0.5 mL per dose for 2 doses administered ≥3 weeks apart.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.